chartexchange

PHAT
Phathom Pharmaceuticals, Inc. Common Stock
stockNASDAQ

Market OpenNov 19, 2026 3:30:47 PM EST
5.05USD-4.717%(-0.25)647,113
5.0300Bid5.0500Ask0.0200Spread
Loading…
Loading…
411.34M
Healthcare
Biotechnology
HQ
Florham Park, NJ, USA
Previous Close
$5.30
Beta
0.97
52-Week High
$18.31 2025-12-23
52-Week Low
$5.02 2026-10-23
SMA 50
$6.75
SMA 200
$9.90
Avg. Vol 10D
1.48M
Avg. Vol 30D
1.69M
Avg. Vol 90D
1.47M
Relative Vol
0.38
65.57M
0.4200%
1,000,000
81,391
PHAT Profile

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.

PHAT Performance
PeriodPriceDateChangeBeta
1W6.232026-11-12-18.78%0.083
1M7.012026-10-19-27.82%2.579
3M9.322026-08-19-45.71%2.257
6M11.402026-05-19-55.61%0.959
1Y14.792025-11-19-65.79%0.966
2Y9.372024-11-19-46.00%—
5Y20.082021-11-19-74.80%1.366
PHAT Stock Summary

Phathom Pharmaceuticals, Inc. Common Stock (NASDAQ:PHAT) stock price today is $5.06, and today's volume is 647,365. PHAT is down 4.528% today. The 30 day average volume is 1.69M. PHAT market cap is $411.34M with 81.29M shares outstanding.